Tempus Beats Estimates with Strong Oncology Diagnostics Growth
Tempus reported strong Q1 2026 profits, exceeding analyst estimates, driven by oncology diagnostics and AI services. Despite a widened net loss, the firm raised full-year revenue guidance and announced key partnerships with Merck and Gilead.